Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs

BMJ Open Diabetes Res Care. 2020 Nov;8(2):e001540. doi: 10.1136/bmjdrc-2020-001540.

Abstract

Introduction: The insulinotropic capacity of exogenous glucagon like peptide-1 (GLP-1) is reduced in type 2 diabetes and the insulin-resistant obese. We have tested the hypothesis that this response is the consequence of a reduced pancreatic GLP-1 receptor (GLP-1r) density in insulin-resistant obese animals.

Research design and methods: GLP-1r density was measured in lean and insulin-resistant adult miniature pigs after the administration of a 68Ga-labeled GLP-1r agonist. The effect of hyperinsulinemia on GLP-1r was assessed using sequential positron emission tomography (PET), both in the fasted state and during a clamp. The impact of tissue perfusion, which could account for changes in GLP-1r agonist uptake, was also investigated using 68Ga-DOTA imaging.

Results: GLP-1r binding potential in the obese pancreas was reduced by 75% compared with lean animals. Similar reductions were evident for fat tissue, but not for the duodenum. In the lean group, induced hyperinsulinemia reduced pancreatic GLP-1r density to a level comparable with that of the obese group. The reduction in blood to tissue transfer of the GLP-1r ligand paralleled that of tissue perfusion estimated using 68Ga-DOTA.

Conclusions: These observations establish that a reduction in abdominal tissue perfusion and a lower GLP-1r density account for the diminished insulinotropic effect of GLP-1 agonists in type 2 diabetes.

Keywords: animal experimentation; glucagon-like peptide 1; insulin resistance; positron-emission tomography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / veterinary
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptide-1 Receptor* / metabolism
  • Insulin Resistance
  • Insulin*
  • Pancreas
  • Swine

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Insulin
  • Glucagon-Like Peptide 1